{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:42:42Z","timestamp":1761896562252,"version":"3.41.2"},"reference-count":24,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2017.00294","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T05:58:38Z","timestamp":1497851918000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study"],"prefix":"10.3389","volume":"8","author":[{"given":"Giuseppe","family":"Pontillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirio","family":"Cocozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.3174\/ajnr.A2035","article-title":"JC virus infection of the brain","volume":"31","author":"Bag","year":"2010","journal-title":"AJNR Am J Neuroradiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1212\/NXI.0000000000000223","article-title":"Natalizumab-induced POU2AF1\/Spi-B upregulation: a possible route for PML development","volume":"3","author":"Meira","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","article-title":"Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values","volume":"3","author":"Schwab","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/acn3.114","article-title":"Outcome and survival of asymptomatic PML in natalizumab-treated MS patients","volume":"1","author":"Dong-Si","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fneur.2013.00011","article-title":"Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy","volume":"4","author":"Lind\u00e5","year":"2013","journal-title":"Front Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/jnnp-2016-313772","article-title":"MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance","volume":"87","author":"Wijburg","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/ana.23676","article-title":"Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"72","author":"Yousry","year":"2012","journal-title":"Ann Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1177\/1352458513510224","article-title":"The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"19","author":"Wattjes","year":"2013","journal-title":"Mult Scler"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1177\/1352458515615225","article-title":"Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients","volume":"22","author":"Wattjes","year":"2016","journal-title":"Mult Scler"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.neurad.2015.08.001","article-title":"Use of quantitative susceptibility mapping (QSM) in progressive multifocal leukoencephalopathy","volume":"43","author":"Carra-Dalliere","year":"2016","journal-title":"J Neuroradiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jns.2014.06.018","article-title":"Low signal intensity in U-fiber identified by susceptibility-weighted imaging in two cases of progressive multifocal leukoencephalopathy","volume":"344","author":"Miyagawa","year":"2014","journal-title":"J Neurol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.3174\/ajnr.A4436","article-title":"Brain magnetic susceptibility changes in patients with natalizumab-associated progressive multifocal leukoencephalopathy","volume":"36","author":"Hodel","year":"2015","journal-title":"AJNR Am J Neuroradiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0126835","DOI":"10.1371\/journal.pone.0126835","article-title":"Improving signal-to-noise ratio in susceptibility weighted imaging: a novel multicomponent non-local approach","volume":"10","author":"Borrelli","year":"2015","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0134963","DOI":"10.1371\/journal.pone.0134963","article-title":"A novel multiparametric approach to 3D quantitative MRI of the brain","volume":"10","author":"Palma","year":"2015","journal-title":"PLoS One"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1007\/s00330-016-4245-2","article-title":"In vivo dentate nucleus MRI relaxometry correlates with previous administration of gadolinium-based contrast agents","volume":"26","author":"Tedeschi","year":"2016","journal-title":"Eur Radiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/jnnp.66.4.520","article-title":"Proton magnetic resonance spectroscopy pattern of progressive multifocal leukoencephalopathy in AIDS","volume":"66","author":"Iranzo","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1212\/NXI.0000000000000171","article-title":"7T MRI in natalizumab-associated PML and ongoing MS disease activity: a case study","volume":"2","author":"Sinnecker","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5876798","DOI":"10.1155\/2016\/5876798","article-title":"Progressive multifocal leukoencephalopathy in a multiple sclerosis patient diagnosed after switching from natalizumab to fingolimod","volume":"2016","author":"Sinnecker","year":"2016","journal-title":"Case Rep Neurol Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/ijms17010100","article-title":"Iron in multiple sclerosis and its noninvasive imaging with quantitative susceptibility mapping","volume":"17","author":"Stuber","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3174\/ajnr.A4825","article-title":"Quantitative susceptibility mapping and R2* measured changes during white matter lesion development in multiple sclerosis: myelin breakdown, myelin debris degradation and removal, and iron accumulation","volume":"37","author":"Zhang","year":"2016","journal-title":"AJNR Am J Neuroradiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1093\/brain\/awr278","article-title":"Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla","volume":"134","author":"Bagnato","year":"2011","journal-title":"Brain"},{"key":"B24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/00004728-199503000-00025","article-title":"Progressive multifocal leukoencephalopathy: unusual MR findings","volume":"19","author":"Ng","year":"1995","journal-title":"J Comput Assist Tomogr"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fneur.2017.00294\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T05:58:38Z","timestamp":1497851918000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fneur.2017.00294\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,19]]},"references-count":24,"alternative-id":["10.3389\/fneur.2017.00294"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2017.00294","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2017,6,19]]},"article-number":"294"}}